Advertisement
U.S. markets close in 5 hours 13 minutes
  • S&P 500

    5,252.16
    +3.67 (+0.07%)
     
  • Dow 30

    39,735.29
    -24.79 (-0.06%)
     
  • Nasdaq

    16,402.47
    +2.95 (+0.02%)
     
  • Russell 2000

    2,123.95
    +9.60 (+0.45%)
     
  • Crude Oil

    82.34
    +0.99 (+1.22%)
     
  • Gold

    2,229.70
    +17.00 (+0.77%)
     
  • Silver

    24.78
    +0.03 (+0.11%)
     
  • EUR/USD

    1.0807
    -0.0022 (-0.21%)
     
  • 10-Yr Bond

    4.2060
    +0.0100 (+0.24%)
     
  • dólar/libra

    1.2640
    +0.0002 (+0.01%)
     
  • USD/JPY

    151.2350
    -0.0110 (-0.01%)
     
  • Bitcoin USD

    71,323.25
    +1,469.27 (+2.10%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,960.63
    +28.65 (+0.36%)
     
  • Nikkei 225

    40,168.07
    -594.66 (-1.46%)
     

Raptor receives positive orphan drug opinion from EU committee

Raptor Pharmaceutical announced that it has received a positive opinion from the European Union Committee for Orphan Medicinal Products recommending orphan drug exclusivity for Procysbi gastro-resistant hard capsules for the treatment of proven nephropathic cystinosis. Final adoption of the opinions on drug approval and orphan exclusivity are expected from the European Commission in the coming months.

Advertisement